What is CritiTech?
CritiTech operates as a premier pharmaceutical Contract Development and Manufacturing Organization (CDMO), dedicated to accelerating the drug development lifecycle for its clientele. The company offers a comprehensive suite of services, encompassing pre-formulation, particle engineering, analytical services, and manufacturing. CritiTech leverages proprietary technologies, including Purcision supercritical precipitation and advanced spray drying techniques, to address complex formulation challenges. With a legacy spanning over 125 years, CritiTech collaborates with leading pharmaceutical entities, ensuring the delivery of high-quality outcomes and facilitating the market entry of vital medications.
How much funding has CritiTech raised?
CritiTech has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for CritiTech?
The substantial large-scale late-stage funding positions CritiTech for significant expansion and operational enhancement. This capital infusion is expected to fuel advancements in their proprietary technologies and broaden their service offerings, potentially enabling them to take on more complex and larger-scale manufacturing projects. CritiTech's strategic focus on accelerating drug development, coupled with its established expertise and collaborative approach, suggests a trajectory aimed at solidifying its market leadership and further penetrating the global pharmaceutical supply chain.
See full CritiTech company page
